Business Wire

World’s First End-to-End IoT Subscription Service for Remote Monitoring Launched by Hiber With Oil & Gas Well Integrity Monitoring to Prevent Leakage & Build a More Sustainable Practice

Share

Dutch satellite Internet-of-Things (IoT) solution startup, Hiber, today announces the launch of HiberHilo, its first end-to-end solution for Oil & Gas Well Integrity Monitoring. HiberHilo is also the world’s first subscription service for IoT-enabled remote Oil/Gas Well monitoring and the company will be introducing similar services for other specific use cases in 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201102005336/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

HiberHilo Dashboard (Photo: Business Wire)

There is a growing demand for remote monitoring in industries such as Oil & Gas to create more sustainable and environmentally friendly practices, especially with COVID-19 limiting travel halting routine maintenance checks. However, the IoT SaaS market in this space is nascent and lacks simplicity. Having already been one of the first firms to develop a remote IoT connectivity solution with the launch of its proprietary nano-satellites in 2018, Hiber identified the urgent need for readily available out-the-box end-to-end subscription based offerings. These must be designed bespoke for particular use cases, as well as being simple and efficient for businesses to install and implement.

The HiberHilo solution for Oil & Gas Well Integrity Monitoring is the first offering of this kind that Hiber will launch because this process is currently complex, time-consuming and expensive (costing up to $40,000 per field visit). Additionally, manual monitoring is prone to error and is often not conducted frequently enough.

Monitoring is critical to ensure that anomalies are identified early and addressed - this can include potential leaks which, if left unaddressed, can impact people’s health and safety as well as negatively impact the environment. HiberHilo’s out-of-the-box subscription solution utilises Hiber’s global satellite network to empower organisations to automate continuous annulus pressure and wellhead monitoring of up to 250 wells in a radius of 10km, even in the most remote locations on Earth. Pricing starts at $449 per month per well (1 sensor and a 5 year contract).

The all-in-one product is available as both a starter kit and in the form of an enterprise solution, both of which feature:

  • A pressure and optional temperature sensor to ensure accurate and regular measurements - organisations can add more sensors to the network if required
  • Easy connectivity anywhere, sending up to 24 messages a day or one per hour
  • Alarm and alert settings
  • An intuitive dashboard for desktop and mobile
  • Support both on-site and via mobile

Coen Janssen, co-founder and Chief Strategy Officer at Hiber said, “We are excited to launch this first-of-its-kind IoT proposition for remote monitoring at a time when it is needed more than ever. HiberHilo has already been proven by Nederlandse Aardolie Maatschappij (NAM) and Royal Dutch Shell (better known as just “Shell”) on an abandoned on-shore well. This technology can be installed in less than 2 hours and within 0.25% accuracy levels of a traditional wired system, which is extremely reliable.”

“We look forward to more companies embracing this new proposition as it will save them time, money and lives by allowing teams to monitor well integrity from home as well as reducing the risk of well integrity issues to create more sustainable practices. The future for remote monitoring is very bright!”

Hiber entered the market in 2018 purely as a connectivity provider, utilising its own proprietary nano-satellite technology to unlock IoT connectivity in the 90% of the world without it. For more information on HiberHilo visit: hiberhilo.com or watch this video.

-- ENDS --

About Hiber

Hiber is an Internet of Things (IoT) solution startup, founded and led by a dream team of satellite experts and tech entrepreneurs. These 'Hibernauts' are working on a moonshoot goal: to launch and provide end-to-end IoT solutions connected by satellites in space. More than 55 employees work on the ground-breaking technology behind Hiber and Hiberband at its offices in the Netherlands and USA.

To date, the company has managed to attract significant funding. This has meant that in November 2018 Hiber became the Netherlands’ first commercial satellite company, launching its first two nano-satellites into orbit. Hiber officially launched at the Amazon Web Services’ (AWS) Re:invent Conference in November 2018 where they were named Commercial Startup Launch of 2018 at the AWS conference.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

JasperFassaert
pr@hiber.global

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye